Corbus CEO Yuval Cohen: Upcoming Catalysts, CRB-701 Oncology and CRB-913 Obesity Clinical Trial Data

Corbus Pharmaceuticals is a clinical-stage biotech company based outside Boston, Massachusetts, advancing a pipeline of innovative therapies in oncology and obesity. The company has several key upcoming catalysts, including: Updated CRB-701 monotherapy oncology data (2nd line) at ASCO in late May/early June Topline results from the CRB-913 obesity trial later this summer Combination data for CRB-701 with Keytruda in 1st-line head & neck cancer expected in Q4 Pipeline Overview: CRB-701 (Oncology) CRB-701 is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4 expression on cancer cells. It is currently being developed for: Head & Neck Squamous Cell Carcinoma Cervical cancer Phase 1/2 data presented at ESMO (Q4 2025) showed encouraging results, including: 47.6% objective response rate (ORR) in head & neck cancer 37.5% ORR in cervical cancer 55.6% ORR in bladder cancer The drug also demonstrated a favorable safety and tolerability profile. CRB-701 may have a potential advantage in HPV-positive cancers, where other therapies targeting the EGFR pathway have shown reduced effectiveness. The FDA has granted Fast Track designation for CRB-701 in both head & neck and cervical cancers. Corbus plans to initiate a registrational trial in head & neck cancer this summer. CRB-913 (Obesity) CRB-913 is a peripherally restricted CB1 receptor inverse agonist designed to treat obesity while minimizing central nervous system side effects. Phase 1a data showed: 2.9% weight loss at 14 days No reports of nausea, vomiting, or constipation Favorable neuropsychiatric profile The ongoing Phase 1b “CANYON-1” study is evaluating multiple dose levels in 240 patients, with topline results expected later this summer. Company Snapshot: Ticker: CRBP (NASDAQ) Market cap: ~$180M USD Cash: $163.3M (as of Dec 31, 2025) Runway into 2028 Corbus is focused on developing differentiated therapies with the potential to address significant unmet needs in cancer and metabolic disease. Podcast produced by Elyssa Carroll Goldman